Medication Risk Management for New Zealand Insurers

Strengthen claims assessment and member outcomes through specialist pharmacy expertise

Published: 3 April 2026 | Updated: 3 April 2026

Medication Risk in NZ Insurance Claims

New Zealand insurers face growing medication complexity in life insurance, income protection, and specialty insurance claims. Your members often have multiple chronic conditions and complex medication regimes. Yet medication management is rarely assessed with the rigour that diagnosis receives. A claimant's medication profile reveals whether conditions are stable, whether management is evidence-based, and whether functional capacity aligns with medical claims.

You need specialist pharmacy expertise integrated into your claims assessment process. IMM's pharmacist-led reviews provide independent medication analysis tailored to NZ therapeutic guidelines, medical practice, and insurance claim requirements. Our reviews strengthen your claims decisions through evidence-based medication assessment across your entire New Zealand insurance portfolio.

Medication Risk Across NZ Insurance Products

Life Insurance Claims

Complex medication regimes often signal ongoing medical instability. We assess medication appropriateness, identify safety concerns, and determine whether medications support stability or suggest uncontrolled conditions. Multi-medication therapy that is not achieving disease control is a red flag for claim risk.

Income Protection Claims

Medication side effects often limit work capacity more than underlying conditions. We identify sedating, cognitively-impairing, or balance-affecting medications that may be primary barriers to return to work. We assess whether medication adjustment could enable functional improvement and earlier return to work.

Disability Claims

For total and permanent disability assessment, we examine whether medication regimes reflect genuine permanent medical needs or whether deprescribing is feasible, suggesting reversibility. Medication complexity without proportional disease control is a red flag for over-treatment rather than genuine permanent disability.

Critical Illness Claims

Medication regimes in critical illness claims reveal existing health risk that may affect claim probability. We assess medication-related complications, interactions, and management issues that may increase claim risk or affect outcome probability.

How Medication Review Informs NZ Insurance Decisions

Key Medication Risk Indicators in NZ Claims

Multiple medications with overlapping mechanisms: Suggests either poor disease control despite treatment or inadequate prescriber coordination. Either indicates heightened claim risk.

Medications prescribed beyond recommended duration: Benzodiazepines beyond 4 weeks, long-term opioids, or other medications typically prescribed short-term, signal medication dependency risk or inadequate disease management.

High doses exceeding evidence recommendations: May indicate either inadequate disease control despite treatment (higher claim risk) or over-treatment (suggests reversibility).

Contraindicated drug combinations: Indicates inadequate prescriber oversight or medication management breakdown. Creates safety risk independent of underlying disease.

Medications not aligned with documented diagnoses: Suggests either undisclosed conditions or inappropriate prescribing. Requires investigation for accurate claims assessment.

Claimant's functional capacity inconsistent with medication-supported disease control: Red flag for credibility assessment. If appropriate medications should enable higher capacity than claimed, discrepancy warrants investigation.

Real-World Example: NZ Life Insurance Claim

Situation: A 52-year-old New Zealand member lodges a life insurance claim citing multiple conditions requiring ongoing medical support. Medical summary shows: depression (controlled), anxiety (controlled), hypertension (controlled), type 2 diabetes (controlled). Current medications: sertraline 100mg, alprazolam 2mg daily, metoprolol, lisinopril, atorvastatin, metformin, and omeprazole. Medical records describe member as "medically stable" with "good disease control."

IMM Review Findings: Medication regime contradicts "good disease control" narrative. Alprazolam 2mg daily is a high dose contraindicated for long-term use, indicating benzodiazepine dependency and ongoing high anxiety despite sertraline therapy. Sertraline at 100mg daily with ongoing high anxiety suggests inadequate depression/anxiety control despite antidepressant dosing. Omeprazole prescribed prophylactically despite no documented GI disease. Beta-blocker and ACE inhibitor combination for hypertension is appropriate, but higher medication burden suggests complex blood pressure management. Overall picture: medical "stability" is medication-dependent, unstable (benzodiazepine dependency), and potentially reversible with medication optimisation.

Outcome: IMM's review reveals significant gaps between the member's stated disease control and medication reality. Claim assessment is significantly more cautious. Ongoing dependency on benzodiazepines, inadequate anxiety control despite antidepressant therapy, and medication-driven instability outweigh the "controlled" disease narrative. Enhanced underwriting or claim conditions are applied.

Medication Review Across NZ Insurance Product Types

Implementation: Building Medication Review Into Your NZ Process

For claims teams: Identify claims with complex medications or multiple chronic conditions. Request pharmacy review during claim assessment to inform your decision-making with evidence-based medication analysis.

For underwriting: Use medication review findings to enhance underwriting accuracy. Medication appropriateness and complexity directly inform medical stability assessment.

For product development: Consider medication review as a standard assessment tool for complex claims across your product portfolio. Evidence-based medication assessment strengthens claims accuracy and supports consistent decision-making.